

REFERENCES

1. Parkin, DM: Global cancer statistics in the year 2000. *Lancet Oncol*, 2: 533-43, 2001.
2. Parkin, DM, Bray, F, Ferlay, J, Pisani, P: Global cancer statistics, 2002. *CA Cancer J Clin*, 55: 74-108, 2005.
3. Sriplung, H, Sontipong, S, Martin, N, Wiangnon, S, Vootiprux, V, Cheirsilpa, A, et al.: Cancer incidence in Thailand, 1995-1997. *Asian Pac J Cancer Prev*, 6: 276-81, 2005.
4. Simarak, S, de Jong, UW, Breslow, N, Dahl, CJ, Ruckphaopunt, K, Scheelings, P, et al.: Cancer of the oral cavity, pharynx/larynx and lung in North Thailand: case-control study and analysis of cigar smoke. *Br J Cancer*, 36: 130-40, 1977.
5. Nakachi, K, Limtrakul, P, Sonklin, P, Sonklin, O, Jarern, CT, Lipigorngoson, S, et al.: Risk factors for lung cancer among Northern Thai women: epidemiological, nutritional, serological, and bacteriological surveys of residents in high- and low-incidence areas. *Jpn J Cancer Res*, 90: 1187-95, 1999.
6. Suttajit, M, Morakote, N, Imai, K, Nakachi, K, Fujiki, H: Takeo Wada Cancer Research Symposium in Chiang Mai. *Jpn J Cancer Res*, 92: 583-5, 2001.

7. Vinitketkumnuen, U, Kalayanamitra, K, Chewonarin, T, Kamens, R: Particulate matter, PM 10 & PM 2.5 levels, and airborne mutagenicity in Chiang Mai, Thailand. *Mutat Res*, 519: 121-31, 2002.
8. Thompson, IM, Pauler, DK, Goodman, PJ, Tangen, CM, Lucia, MS, Parnes, HL, et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level \leq 4.0 ng per milliliter. *N Engl J Med*, 350: 2239-46, 2004.
9. Nadler, RB, Humphrey, PA, Smith, DS, Catalona, WJ, Ratliff, TL: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. *J Urol*, 154: 407-13, 1995.
10. Potts, JM: Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. *J Urol*, 164: 1550-3, 2000.
11. Stamey, TA, Yang, N, Hay, AR, McNeal, JE, Freiha, FS, Redwine, E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. *N Engl J Med*, 317: 909-16, 1987.
12. Stancik, I, Luftenegger, W, Klimpfinger, M, Muller, MM, Hoeltl, W: Effect of NIH-IV prostatitis on free and free-to-total PSA. *Eur Urol*, 46: 760-4, 2004.
13. Kakehi, Y, Kamoto, T, Shiraishi, T, Kato, T, Tobisu, K, Akakura, K, et al.: Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. *Eur Urol*, 41: 47-53, 2002.
14. Graefen, M, Karakiewicz, PI, Cagiannos, I, Quinn, DI, Henshall, SM, Grygiel, JJ, et al.: International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. *J Clin Oncol*, 20: 3206-12, 2002.

15. Ravery, V, Boccon-Gibod, LA, Meulemans, A, Dauge-Geffroy, MC, Toubanc, M, Boccon-Gibod, L: Predictive value of pathological features for progression after radical prostatectomy. *Eur Urol*, 26: 197-201, 1994.
16. Dunn, GP, Bruce, AT, Ikeda, H, Old, LJ, Schreiber, RD: Cancer immunoediting: from immunosurveillance to tumor escape. *Nat Immunol*, 3: 991-8, 2002.
17. Zhang, JY: Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. *Cancer Detect Prev*, 28: 114-8, 2004.
18. Altieri, DC: Survivin, versatile modulation of cell division and apoptosis in cancer. *Oncogene*, 22: 8581-9, 2003.
19. Adida, C, Crotty, PL, McGrath, J, Berrebi, D, Diebold, J, Altieri, DC: Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. *Am J Pathol*, 152: 43-9, 1998.
20. Chakravarti, A, Noll, E, Black, PM, Finkelstein, DF, Finkelstein, DM, Dyson, NJ, et al.: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. *J Clin Oncol*, 20: 1063-8, 2002.
21. Gazzaniga, P, Gradilone, A, Giuliani, L, Gandini, O, Silvestri, I, Nofroni, I, et al.: Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. *Ann Oncol*, 14: 85-90, 2003.
22. Kato, J, Kuwabara, Y, Mitani, M, Shinoda, N, Sato, A, Toyama, T, et al.: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. *Int J Cancer*, 95: 92-5, 2001.

23. Monzo, M, Rosell, R, Felip, E, Astudillo, J, Sanchez, JJ, Maestre, J, et al.: A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. *J Clin Oncol*, 17: 2100-4, 1999.
24. Sarela, AI, Macadam, RC, Farmery, SM, Markham, AF, Guillou, PJ: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. *Gut*, 46: 645-50, 2000.
25. Sui, L, Dong, Y, Ohno, M, Watanabe, Y, Sugimoto, K, Tokuda, M: Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. *Int J Oncol*, 21: 315-20, 2002.
26. Swana, HS, Grossman, D, Anthony, JN, Weiss, RM, Altieri, DC: Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. *N Engl J Med*, 341: 452-3, 1999.
27. Takai, N, Miyazaki, T, Nishida, M, Nasu, K, Miyakawa, I: Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. *Int J Mol Med*, 10: 211-6, 2002.
28. Yagihashi, A, Asanuma, K, Kobayashi, D, Tsuji, N, Shijubo, Y, Abe, S, et al.: Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. *Lung Cancer*, 48: 217-21, 2005.
29. Yagihashi, A, Asanuma, K, Tsuji, N, Torigoe, T, Sato, N, Hirata, K, et al.: Detection of anti-livin antibody in gastrointestinal cancer patients. *Clin Chem*, 49: 1206-8, 2003.

30. Yagihashi, A, Ohmura, T, Asanuma, K, Kobayashi, D, Tsuji, N, Torigoe, T, et al.: Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. *Clin Chim Acta*, 362: 125-30, 2005.
31. Hajra, KM, Liu, JR: Apoptosome dysfunction in human cancer. *Apoptosis*, 9: 691-704, 2004.
32. Kitamura, H, Honma, I, Torigoe, T, Hariu, H, Asanuma, H, Hirohashi, Y, et al.: Expression of livin in renal cell carcinoma and detection of anti-livin autoantibody in patients. *Urology*, 70: 38-42, 2007.
33. Raff, M: Cell suicide for beginners. *Nature*, 396: 119-22, 1998.
34. Rohayem, J, Diestelkoetter, P, Weigle, B, Oehmichen, A, Schmitz, M, Mehlhorn, J, et al.: Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. *Cancer Res*, 60: 1815-7, 2000.
35. Thompson, CB: Apoptosis in the pathogenesis and treatment of disease. *Science*, 267: 1456-62, 1995.
36. Yagihashi, A, Asanuma, K, Nakamura, M, Araya, J, Mano, Y, Torigoe, T, et al.: Detection of anti-survivin antibody in gastrointestinal cancer patients. *Clin Chem*, 47: 1729-31, 2001.
37. Zhang, JY, Casiano, CA, Peng, XX, Koziol, JA, Chan, EK, Tan, EM: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. *Cancer Epidemiol Biomarkers Prev*, 12: 136-43, 2003.
38. Shivapurkar, N, Reddy, J, Chaudhary, PM, Gazdar, AF: Apoptosis and lung cancer: a review. *J Cell Biochem*, 88: 885-98, 2003.

39. Nicholson, DW, Thornberry, NA: Caspases: killer proteases. *Trends Biochem Sci*, 22: 299-306, 1997.
40. Degtarev, A, Boyce, M, Yuan, J: A decade of caspases. *Oncogene*, 22: 8543-67, 2003.
41. Delhalle, S, Duvoix, A, Schnekenburger, M, Morceau, F, Dicato, M, Diederich, M: An introduction to the molecular mechanisms of apoptosis. *Ann NY Acad Sci*, 1010: 1-8, 2003.
42. Liu, B, Han, M, Wen, JK, Wang, L: Livin/ML-IAP as a new target for cancer treatment. *Cancer Lett*, 250: 168-76, 2007.
43. Ambrosini, G, Adida, C, Altieri, DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. *Nat Med*, 3: 917-21, 1997.
44. Ashhab, Y, Alian, A, Polliack, A, Panet, A, Ben Yehuda, D: Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. *FEBS Lett*, 495: 56-60, 2001.
45. Kasof, GM, Gomes, BC: Livin, a novel inhibitor of apoptosis protein family member. *J Biol Chem*, 276: 3238-46, 2001.
46. Lin, JH, Deng, G, Huang, Q, Morser, J: KIAP, a novel member of the inhibitor of apoptosis protein family. *Biochem Biophys Res Commun*, 279: 820-31, 2000.
47. Nakamura, M, Tsuji, N, Asanuma, K, Kobayashi, D, Yagihashi, A, Hirata, K, et al.: Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. *Cancer Sci*, 95: 44-51, 2004.

48. Tanabe, H, Yagihashi, A, Tsuji, N, Shijubo, Y, Abe, S, Watanabe, N: Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. *Lung Cancer*, 46: 299-304, 2004.
49. Vucic, D, Stennicke, HR, Pisabarro, MT, Salvesen, GS, Dixit, VM: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. *Curr Biol*, 10: 1359-66, 2000.
50. Badran, A, Yoshida, A, Ishikawa, K, Goi, T, Yamaguchi, A, Ueda, T, et al.: Identification of a novel splice variant of the human anti-apoptosis gene survivin. *Biochem Biophys Res Commun*, 314: 902-7, 2004.
51. Caldas, H, Honsey, LE, Altura, RA: Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. *Mol Cancer*, 4: 11, 2005.
52. Mahotka, C, Wenzel, M, Springer, E, Gabbert, HE, Gerharz, CD: Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. *Cancer Res*, 59: 6097-102, 1999.
53. Kobayashi, K, Hatano, M, Otaki, M, Ogasawara, T, Tokuhisa, T: Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. *Proc Natl Acad Sci U S A*, 96: 1457-62, 1999.
54. Velculescu, VE, Madden, SL, Zhang, L, Lash, AE, Yu, J, Rago, C, et al.: Analysis of human transcriptomes. *Nat Genet*, 23: 387-8, 1999.
55. Hirohashi, Y, Torigoe, T, Maeda, A, Nabeta, Y, Kamiguchi, K, Sato, T, et al.: An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. *Clin Cancer Res*, 8: 1731-9, 2002.

56. Fortugno, P, Wall, NR, Giodini, A, O'Connor, DS, Plescia, J, Padgett, KM, et al.: Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. *J Cell Sci*, 115: 575-85, 2002.
57. Dohi, T, Beltrami, E, Wall, NR, Plescia, J, Altieri, DC: Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. *J Clin Invest*, 114: 1117-27, 2004.
58. Hofmann, HS, Simm, A, Hammer, A, Silber, RE, Bartling, B: Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. *J Cancer Res Clin Oncol*, 128: 554-60, 2002.
59. Ikehara, M, Oshita, F, Kameda, Y, Ito, H, Ohgane, N, Suzuki, R, et al.: Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. *Oncol Rep*, 9: 835-8, 2002.
60. Adida, C, Berrebi, D, Peuchmaur, M, Reyes-Mugica, M, Altieri, DC: Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. *Lancet*, 351: 882-3, 1998.
61. Adida, C, Haioun, C, Gaulard, P, Lepage, E, Morel, P, Briere, J, et al.: Prognostic significance of survivin expression in diffuse large B-cell lymphomas. *Blood*, 96: 1921-5, 2000.
62. Kappler, M, Kohler, T, Kampf, C, Diestelkötter, P, Wurl, P, Schmitz, M, et al.: Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. *Int J Cancer*, 95: 360-3, 2001.
63. Grabowski, P, Kuhnel, T, Muhr-Wilkenshoff, F, Heine, B, Stein, H, Hopfner, M, et al.: Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. *Br J Cancer*, 88: 115-9, 2003.

64. Franklin, MC, Kadkhodayan, S, Ackerly, H, Alexandru, D, Distefano, MD, Elliott, LO, et al.: Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). *Biochemistry*, 42: 8223-31, 2003.
65. Crnkovic-Mertens, I, Semzow, J, Hoppe-Seyler, F, Butz, K: Isoform-specific silencing of the Livin gene by RNA interference defines Livin beta as key mediator of apoptosis inhibition in HeLa cells. *J Mol Med*, 84: 232-40, 2006.
66. Andersen, MH, Reker, S, Becker, JC, thor Straten, P: The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. *J Invest Dermatol*, 122: 392-9, 2004.
67. Angelopoulou, K, Diamandis, EP: Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. *Eur J Cancer*, 33: 115-21, 1997.
68. Angelopoulou, K, Diamandis, EP, Sutherland, DJ, Kellen, JA, Bunting, PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. *Int J Cancer*, 58: 480-7, 1994.
69. Angelopoulou, K, Rosen, B, Stratis, M, Yu, H, Solomou, M, Diamandis, EP: Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. *Cancer*, 78: 2146-52, 1996.
70. Green, JA, Robertson, LJ, Campbell, IR, Jenkins, J: Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. *Cancer Detect Prev*, 19: 151-5, 1995.

71. Guinee, DG, Jr., Travis, WD, Trivers, GE, De Benedetti, VM, Cawley, H, Welsh, JA, et al.: Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. *Carcinogenesis*, 16: 993-1002, 1995.
72. Wild, CP, Ridanpaa, M, Anttila, S, Lubin, R, Soussi, T, Husgafvel-Pursiainen, K, et al.: p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. *Int J Cancer*, 64: 176-81, 1995.
73. Davidoff, AM, Iglehart, JD, Marks, JR: Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. *Proc Natl Acad Sci U S A*, 89: 3439-42, 1992.
74. Houbiers, JG, van der Burg, SH, van de Watering, LM, Tollenaar, RA, Brand, A, van de Velde, CJ, et al.: Antibodies against p53 are associated with poor prognosis of colorectal cancer. *Br J Cancer*, 72: 637-41, 1995.
75. Mudenda, B, Green, JA, Green, B, Jenkins, JR, Robertson, L, Tarunina, M, et al.: The relationship between serum p53 autoantibodies and characteristics of human breast cancer. *Br J Cancer*, 69: 1115-9, 1994.
76. Bourhis, J, Lubin, R, Roche, B, Koscielny, S, Bosq, J, Dubois, I, et al.: Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. *J Natl Cancer Inst*, 88: 1228-33, 1996.
77. Cressey, R, Pimpa, S, Chewaskulyong, B, Lertprasertsuke, N, Saeteng, S, Tayapiwatana, C, et al.: Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients. *BMC Biotechnol*, 8: 16, 2008.

78. Falleni, M, Pellegrini, C, Marchetti, A, Oprandi, B, Buttitta, F, Barassi, F, et al.: Survivin gene expression in early-stage non-small cell lung cancer. *J Pathol*, 200: 620-6, 2003.
79. Shariat, SF, Casella, R, Khoddami, SM, Hernandez, G, Sulser, T, Gasser, TC, et al.: Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. *J Urol*, 171: 626-30, 2004.
80. Smith, SD, Wheeler, MA, Plescia, J, Colberg, JW, Weiss, RM, Altieri, DC: Urine detection of survivin and diagnosis of bladder cancer. *JAMA*, 285: 324-8, 2001.
81. Weikert, S, Christoph, F, Schrader, M, Krause, H, Miller, K, Muller, M: Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. *Int J Cancer*, 116: 100-4, 2005.
82. Carpagnano, GE, Spanevello, A, Palladino, GP, Gramiccioni, C, Ruggieri, C, Carpagnano, F, et al.: Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: how hot is the link? *Lung Cancer*, 67: 108-13,
83. Wu, YK, Chen, KT, Kuo, YB, Huang, YS, Chan, EC: Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer. *Cancer Lett*, 273: 331-5, 2009.
84. Yie, SM, Lou, B, Ye, SR, He, X, Cao, M, Xie, K, et al.: Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. *Lung Cancer*, 63: 284-90, 2009.

85. Karanikas, V, Khalil, S, Kerenidi, T, Gourgoulianis, KI, Germenis, AE: Anti-survivin antibody responses in lung cancer. *Cancer Lett*, 282: 159-66, 2009.
86. Andersen, MH, Becker, JC, Straten, P: Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP. *J Invest Dermatol*, 122: 1336-7, 2004.
87. Reker, S, Meier, A, Holten-Andersen, L, Svane, IM, Becker, JC, thor Straten, P, et al.: Identification of novel survivin-derived CTL epitopes. *Cancer Biol Ther*, 3: 173-9, 2004.
88. Jin, Q, Menter, DG, Mao, L, Hong, WK, Lee, HY: Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. *Carcinogenesis*, 29: 1614-22, 2008.